Company: DMAAR
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005176
Chunk: 290

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-22
Form: POS AM
Chunk 290
---
 to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is theretofore unenforceable. ITEM 15. RECENT SALES OF UNREGISTERED SECURITIES. On June 17, 2024, Drugs Made In America Acquisition LLC, our sponsor, paid certain offering costs totaling $35,000, or approximately $0.0016 per share, in exchange for an aggregate of 22,361,111 ordinary shares, par value $0.0001 per share. On November6, 2024, the sponsor surrendered and forfeited 12,503,968 ordinary shares to us for no consideration, following which the sponsor holds 9,857,143 founder shares. The number of founder shares issued was determined based on the expectation that the founder shares would represent 30% of the issued and outstanding ordinary shares upon completion of this offering (not including the private units and the representative shares and assuming the sponsor does not purchase units in this offering). Such securities were issued in connection with our incorporation pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act. Our sponsor is an accredited investor for purposes of Rule 501 of Regulation D. In addition, our sponsor has committed to purchase from us an aggregate of 400,000 private units (or 430,000 private units if the underwriters’ option to purchase additional units is exercised in full) at a price of $10.00 per unit ($4,000,000 in the aggregate, or $4,300,000 in the aggregate if the underwriters’ option to purchase additional units is exercised in full). This purchase will take place on a private placement basis simultaneously with the completion of our initial public offering. This issuance will be made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act. No underwriting discounts or commissions were paid with respect to such sales.

II-1

ITEM 16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES. (a) Exhibits.The following exhibits are being filed herewith:

| Exhibit |     | Description                                                                                                                        |
| 1.1*    |     | Form of Underwriting Agreement                                                                                                     |
| 3.1*    |     | Memorandum and Articles of Association                                                                                             |
| 3.2*    |     | Amended and Restated Memorandum and Articles of Association